{"id":1065165,"date":"2012-08-24T08:10:20","date_gmt":"2012-08-24T08:10:20","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/new-partnership-to-drive-mass-production-of-life-saving-stem-cells\/"},"modified":"2024-08-18T11:09:55","modified_gmt":"2024-08-18T15:09:55","slug":"new-partnership-to-drive-mass-production-of-life-saving-stem-cells","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/diseases\/new-partnership-to-drive-mass-production-of-life-saving-stem-cells.php","title":{"rendered":"New Partnership to Drive Mass Production of Life-Saving Stem Cells"},"content":{"rendered":"<p><p>    TORONTO, ONTARIO--(Marketwire -08\/23\/12)- Stem cells hold great    promise for treating and curing numerous diseases; however, a    major challenge facing scientists is how to produce stem cells    in the massive quantities required for clinical use. The        McEwen Centre for Regenerative Medicine (McEwen Centre) and    the     Centre for Commercialization of Regenerative Medicine    (CCRM) are partnering to establish a fund that will drive    research in this area.  <\/p>\n<p>    The McEwen Centre-CCRM Commercialization Impact Prize launches    today, and will solicit innovative ideas from regenerative    medicine scientists working in labs throughout the McEwen    Centre. The winning team(s) will be awarded up to $600,000 to    pursue research that will determine how to manufacture stem    cells for clinical use and drug screening.  <\/p>\n<p>    \"This private-public funding partnership is an important step    forward to accelerating the advance of a discovery from a lab    bench to the patient and onto the global market. Scientists at    the McEwen Centre are making significant progress towards    finding a cure for diseases such as Type 1 diabetes and heart    disease. Collaborative partnerships are the key to discovering    the cures sooner!\" says Rob McEwen, co-founder of the McEwen    Centre, and Chief Owner, McEwen Mining.  <\/p>\n<p>    Deadline for submissions is October 15, 2012. The Prize will    fund up to two, 2-year projects that address the following    challenges:  <\/p>\n<p>    \"Overcoming the scale-up and manufacturing challenge of stem    cells would be a huge advancement for the regenerative medicine    (RM) industry and this initiative fits in perfectly with our    mandate to bridge the RM commercialization gap,\" explains Dr.    Michael May, CEO of the Centre for Commercialization of    Regenerative Medicine. \"We're very pleased to be working with    the McEwen Centre, already a partner of ours, to make this    happen.\"  <\/p>\n<p>    The Commercialization Impact Prize budget template and    application form can be found here:     <a href=\"http:\/\/ccrm.ca\/Commercialization-Impact-Prize\" rel=\"nofollow\">http:\/\/ccrm.ca\/Commercialization-Impact-Prize<\/a> or     <a href=\"http:\/\/mcewencentre.com\/ccrm\" rel=\"nofollow\">http:\/\/mcewencentre.com\/ccrm<\/a>.  <\/p>\n<p>    About McEwen Centre for Regenerative Medicine  <\/p>\n<p>    The McEwen Centre for Regenerative Medicine was founded by Rob    and Cheryl McEwen in 2003 and opened its doors in 2006. The    McEwen Centre for Regenerative Medicine, part of Toronto-based    University Health Network, is a world leading centre for stem    cell research, facilitating collaboration between renowned    scientists from 5 major hospitals in Toronto, the University of    Toronto and around the world. Supported by philanthropic    contributions and research grants, McEwen Centre scientists    strive to introduce novel regenerative therapies for    debilitating and life threatening illnesses including heart    disease, spinal cord injury, diabetes, diseases of the blood,    liver and arthritis.  <\/p>\n<p>    About Centre for Commercialization of Regenerative Medicine    (CCRM)  <\/p>\n<p>        CCRM, a Canadian not-for-profit organization funded by the    Government of Canada's Networks of Centres of Excellence    program and six institutional partners, supports the    development of technologies that accelerate the    commercialization of stem cell- and biomaterials-based    technologies and therapies. A network of academics, industry    and entrepreneurs, CCRM translates scientific discoveries into    marketable products for patients. CCRM launched in Toronto's    Discovery District on June 14, 2011.  <\/p>\n<\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/partnership-drive-mass-production-life-110000309.html;_ylt=A2KJjbzfNjdQYkkAHsr_wgt.\" title=\"New Partnership to Drive Mass Production of Life-Saving Stem Cells\" rel=\"noopener\">New Partnership to Drive Mass Production of Life-Saving Stem Cells<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> TORONTO, ONTARIO--(Marketwire -08\/23\/12)- Stem cells hold great promise for treating and curing numerous diseases; however, a major challenge facing scientists is how to produce stem cells in the massive quantities required for clinical use. The McEwen Centre for Regenerative Medicine (McEwen Centre) and the Centre for Commercialization of Regenerative Medicine (CCRM) are partnering to establish a fund that will drive research in this area. The McEwen Centre-CCRM Commercialization Impact Prize launches today, and will solicit innovative ideas from regenerative medicine scientists working in labs throughout the McEwen Centre.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/diseases\/new-partnership-to-drive-mass-production-of-life-saving-stem-cells.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246871],"tags":[],"class_list":["post-1065165","post","type-post","status-publish","format-standard","hentry","category-diseases"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1065165"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1065165"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1065165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1065165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1065165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1065165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}